Studies indicated that blinatumomab, a bispecific T-cell engager (BiTE) antibody that simultaneously binds with CD19 antigen expressed on the tumor cells and CD3 antigen on T cells, recruits and activates T cells, triggering target-dependent tumor cell killing. This evidence concerns the gene CD19 and neoplasm.